Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 160,000 Shares

Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) insider Robert Berman sold 160,000 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $25.76, for a total value of $4,121,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Robert Berman also recently made the following trade(s):

  • On Thursday, November 9th, Robert Berman sold 27,423 shares of Biohaven Pharmaceutical Holding Co stock. The shares were sold at an average price of $26.60, for a total value of $729,451.80.

Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) traded down $1.00 during midday trading on Tuesday, hitting $24.39. The company had a trading volume of 326,430 shares, compared to its average volume of 225,220. Biohaven Pharmaceutical Holding Co Ltd has a 52 week low of $17.00 and a 52 week high of $39.51.

WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 160,000 Shares” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/15/biohaven-pharmaceutical-holding-co-ltd-bhvn-insider-robert-berman-sells-160000-shares.html.

A number of brokerages recently weighed in on BHVN. BidaskClub cut Biohaven Pharmaceutical Holding Co from a “sell” rating to a “strong sell” rating in a report on Tuesday. William Blair reissued an “outperform” rating on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, October 3rd. Piper Jaffray Companies reissued a “buy” rating and set a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, September 12th. Zacks Investment Research raised Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. Finally, Needham & Company LLC decreased their price objective on Biohaven Pharmaceutical Holding Co from $43.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Biohaven Pharmaceutical Holding Co has a consensus rating of “Buy” and a consensus target price of $40.80.

A number of institutional investors have recently made changes to their positions in the business. VHCP Management II LLC purchased a new position in Biohaven Pharmaceutical Holding Co in the 3rd quarter worth approximately $60,826,000. Nicholas Investment Partners LP purchased a new position in Biohaven Pharmaceutical Holding Co in the 3rd quarter worth approximately $3,602,000. California State Teachers Retirement System purchased a new position in Biohaven Pharmaceutical Holding Co in the 3rd quarter worth approximately $635,000. Stifel Financial Corp purchased a new position in Biohaven Pharmaceutical Holding Co in the 3rd quarter worth approximately $15,525,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in Biohaven Pharmaceutical Holding Co in the 3rd quarter worth approximately $1,431,000.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply